Liver disease biotech Vital Therapies files for a $86 million IPO

By
A A A

Vital Therapies, a clincal-stage biotech developing treatments for acute liver failure, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The San Diego, CA-based company, which was founded in 2003, plans to list on the NASDAQ under the symbol VTL. Vital Therapies initially filed confidentially on July 22, 2013. Credit Suisse and William Blair are the joint bookrunners on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks:

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

210,395,138
  • $10 ▼ 19.22%
96,887,808
  • $16.99 ▲ 1.13%
95,228,035
  • $75.86 ▼ 6.08%
56,807,621
  • $11.21 ▼ 4.02%
49,508,265
  • $107.34 ▲ 0.56%
43,870,160
  • $3.35 ▲ 0.60%
39,156,225
  • $42.08 ▼ 3.88%
37,305,534
  • $99.81 ▼ 0.37%
As of 10/29/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com